期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

阿瑞匹坦在实体肿瘤化疗止吐治疗的研究进展 被引量：3

原文传递
导出
摘要 应用化学药物抑制肿瘤细胞的增殖、转移或者杀死肿瘤细胞是治疗肿瘤的3大主要手段之一，又称化疗（chemother-apy）。化疗往往伴随着多种不良反应。化疗所致恶心呕吐（chemotherapy-inducednauseaandvomiting，CINV）是肿瘤患者化疗过程中最常见的不良反应之一。
作者 于莉 张晓晔
机构地区 中国医科大学附属盛京医院第四肿瘤科
出处 《中国肿瘤临床与康复》 2016年第9期1148-1152,共5页 Chinese Journal of Clinical Oncology and Rehabilitation
关键词 阿瑞匹坦 药物疗法 止吐药 Aprepitant Drug therapy Antiemetic drugs
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献41

  • 1Schwartzberg L.Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting[J].Expert Rev Pharmacoecon Outcomes Res,2014,14:825-834.
  • 2Hargreaves R,Ferreira JC,Hughes D,et al.Development of aprepitant,the first neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting[J].Ann NY Acad Sci,2011,1222:40-48.
  • 3Bhandari PR.Recent advances in pharmacotherapy of chemotherapy-induced nausea and vomiting[J].J Adv Pharm Technol Res,2012,3:202-209.
  • 4Aapro M,Carides A,Rapoport BL,et al.Aprepitant and fosaprepitant:a 10-year review of efficacy and safety[J].Oncologist,2015,20:450-458.
  • 5Goineau S,Guillaume P,Barrais L,et al.Automated analysis of delayed emesis in the telemetered ferret:detection of synergistic effects of aprepitant and ondansetron[J].Fundam Clin Pharmacol,2014,28:643-651.
  • 6Navari RM.Management of chemotherapy-induced nausea and vomiting:focus on newer agents and new uses for older agents[J].Drugs,2013,73:249-262.
  • 7Van den Brande J,Brouwer A,Peeters M.Use of antiemetics in the prevention of chemotherapy-induced nausea and vomiting:review and focus on the belgian situation[J].Acta Gastroenterol Belg,2014,77:240-248.
  • 8陈露露,王亚芹,欧阳冬生.化疗止吐药物的研究进展[J].肿瘤药学,2014,4(2):107-111. 被引量：25
  • 9Hawkins R,Grunberg S.Chemotherapy-induced nausea and vomiting:challenges and opportunities for improved patient outcomes[J].Clin J Oncol Nurs,2009,13:54-64.
  • 10Hesketh PJ.Chemotherapy-induced nausea and vomiting.N Engl J Med[J].2008,358:2482-2494.

二级参考文献73

  • 1聂映,毕小玲,尤启冬.阿瑞吡坦[J].中国新药杂志,2006,15(3):238-239. 被引量：16
  • 2Rapoport BL, Jordan K, Boice JA, et al. Aprepitant for the preven- tion of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types : a randomized, double-blind study [ J ]. Support Care Cancer, 2010,18(4) :423-431.
  • 3Hesketh PJ,Aapro M,Street JC,et al. Evaluation of risk factors pre- dictive of nausea and vomiting with current standard-of-care antiemet- ic treatment: analysis of two phase III trials of aprepitant in patients receiving cisplatin-based chemotherapy [ J]. Support Care Cancer, 2010,18(9) :1171-1177.
  • 4Yeo W, Mo FK,Suen J J, et al. A randomized study of aprepitant, on- dansetron and dexamethasone for chemotherapy-induced nausea and vomiting in Chinese breast cancer patients receiving moderately eme- togenic chemotherapy[ J]. Breast Cancer Res Treat, 2009,113 ( 3 ) : 529-535.
  • 5Longo F,Mansueto G, Lapadula V,et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-hased chemother- apy[J], lnt J Clin Pract,2012, 66(8) ;753-757.
  • 6Kariya M, Tanaka K, Matsumoto K, et al. Effects of aprepitant in daily administrations of low-dose cisp|atin[ J . Can To Kagaku Ryo- ho,2012,39(2) :245-250.
  • 7Hesketh PJ, Sanz-Altamira P. Aprepitant, dexamethasone, and pal- onosetron in the prevention of doxorubicin/cyclophosphamide-induced nausea and vomiting[ J]. Support Care Cancer,2012,20(3 ) :653-656.
  • 8Vo TI', Nelson JJ. Cardiovascular events in cancer patients treated with highly or moderately emetogenic chemotherapy: results from a population-based study [ J ]. J Cancer Epidemiol, 2012,2012 : 529- 357.
  • 9Gore L, Chawla S, Petrilli A, et al. Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a ran- domized, double-blind, placebo-controlled study of efficacy and toler- ability [ J ]. Pediatr Blood Cancer, 2009,52 (2) :242-247.
  • 10Sanchez RI, Wang RW, Newton DJ, et al. Cytochrome P4503A4 is the major anzyme involved in the metabolism of the substance P recepter antagonist aprepitant[ J. Drug Metab Dispos, 2004,32( 11 ) : 1287-1292.

共引文献38

同被引文献13

引证文献3

二级引证文献6

中国肿瘤临床与康复
2016年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部